{"disease":{"id":"mhspc","name":"mhspc"},"drugs":{"marketed":[{"drug_id":"abiraterone","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (mHSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT07223372","title":"An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05649943","title":"Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":566,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07395804","title":"How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06019676","title":"Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT07190300","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":155,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07268794","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07181122","title":"Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT06010914","title":"A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06661122","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05956639","title":"Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03899467","title":"The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":true},{"nct_id":"NCT07140900","title":"Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07112612","title":"Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT06479187","title":"PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06312670","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Pedro Barata, MD, MSc","has_results":false},{"nct_id":"NCT05683964","title":"Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}